Contrasting biote (BTMD) and Its Rivals

biote (NASDAQ:BTMD – Get Rating) is one of 58 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its peers? We will compare biote to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares biote and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	56.20%	-46.62%	29.08%
biote Competitors	-10.38%	-101.91%	21.35%

Institutional and Insider Ownership

3.8% of biote shares are held by institutional investors. Comparatively, 14.3% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 16.6% of biote shares are held by company insiders. Comparatively, 21.8% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for biote and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0	0	5	0	3.00
biote Competitors	214	568	818	46	2.42

biote presently has a consensus price target of $10.40, indicating a potential upside of 97.34%. As a group, “Medicinals & botanicals” companies have a potential upside of 109.41%. Given biote’s peers higher possible upside, analysts plainly believe biote has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares biote and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
biote	$164.96 million	-$970,000.00	87.85
biote Competitors	$290.64 million	-$110.28 million	-1.82

biote’s peers have higher revenue, but lower earnings than biote. biote is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

biote has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, biote’s peers have a beta of 1.16, meaning that their average stock price is 16% more volatile than the S&P 500.

Summary

biote beats its peers on 7 of the 13 factors compared.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.